| 1 |
34115701 |
10.1097/RLU.0000000000003750 |
2022 |
Burkitt Lymphoma/Leukemia Presented on 68Ga-Pentixafor and 18F-FDG PET/CT. |
CXCR4 |
| 2 |
34525196 |
10.1182/blood.2021013239 |
2022 |
CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication. |
CXCR4 |
| 3 |
34651291 |
10.1007/s11307-021-01664-3 |
2022 |
CXCR4-Directed PET/CT with [<sup>68</sup>Ga]Pentixafor in Central Nervous System Lymphoma: A Comparison with [<sup>18</sup>F]FDG PET/CT. |
CXCR4 |
| 4 |
34990302 |
10.1080/21655979.2021.2017590 |
2022 |
Propofol induces the apoptosis of neural stem cells via microRNA-9-5p / chemokine CXC receptor 4 signaling pathway. |
CXCR4 |
| 5 |
35020191 |
10.1111/bjh.18036 |
2022 |
Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline. |
CXCR4 |
| 6 |
35037561 |
10.1080/10428194.2021.2020776 |
2022 |
Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia. |
CXCR4 |
| 7 |
35057088 |
10.3390/pharmaceutics14010192 |
2022 |
Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials. |
CXCR4 |
| 8 |
35078860 |
10.1158/1078-0432.CCR-21-3284 |
2022 |
Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands. |
CXCR4 |
| 9 |
35149375 |
10.1016/j.ctarc.2022.100527 |
2022 |
Current approach to Waldenström Macroglobulinemia. |
CXCR4 |
| 10 |
35181615 |
NA |
2022 |
Morphoproteomics Identifies SIRT1, EZH2 and CXCR4 Pathways in Diffuse Large B-Cell Lymphoma: Therapeutic Implications. |
CXCR4 |
| 11 |
35241482 |
10.2967/jnumed.121.263693 |
2022 |
Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using <sup>68</sup>Ga-PentixaFor PET. |
CXCR4 |
| 12 |
35255429 |
10.1016/j.anndiagpath.2021.151886 |
2022 |
De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients. |
CXCR4 |
| 13 |
35339405 |
10.1016/j.clml.2022.02.005 |
2022 |
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. |
CXCR4 |
| 14 |
35385630 |
NA |
2022 |
Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome? |
CXCR4 |
| 15 |
35421785 |
10.1016/j.biopha.2022.112940 |
2022 |
A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4<sup>+</sup> lymphoma cells without toxicity in immunocompromised and immunocompetent mice. |
CXCR4 |
| 16 |
35450208 |
10.1177/20406207221090886 |
2022 |
Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib. |
CXCR4 |
| 17 |
35454017 |
10.3390/diagnostics12040969 |
2022 |
Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance. |
CXCR4 |
| 18 |
35510210 |
10.1177/20406207221093962 |
2022 |
Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond. |
CXCR4 |
| 19 |
35674738 |
10.1007/s00259-022-05849-y |
2022 |
CXCR4-targeted theranostics in oncology. |
CXCR4 |
| 20 |
35695746 |
10.1080/17474086.2022.2089110 |
2022 |
Positron emission tomography/magnetic resonance imaging (PET/MRI) vs. gastroscopy: Can it improve detection of extranodal marginal zone lymphomas of the stomach following <i>H. pylori</i> treatment? |
CXCR4 |
| 21 |
35738903 |
10.2967/jnumed.122.264207 |
2022 |
C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma. |
CXCR4 |
| 22 |
35770040 |
10.2147/TCRM.S338655 |
2022 |
Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First. |
CXCR4 |
| 23 |
35774848 |
10.1155/2022/3276925 |
2022 |
Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics. |
CXCR4 |
| 24 |
35794478 |
10.1038/s41586-022-04906-8 |
2022 |
Super-enhancer hypermutation alters oncogene expression in B cell lymphoma. |
CXCR4 |
| 25 |
35842683 |
10.1186/s13287-022-03011-x |
2022 |
Prostaglandin E1 reduces apoptosis and improves the homing of mesenchymal stem cells in pulmonary arterial hypertension by regulating hypoxia-inducible factor 1 alpha. |
CXCR4 |
| 26 |
35877223 |
10.3390/curroncol29070363 |
2022 |
Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation. |
CXCR4 |
| 27 |
35884548 |
10.3390/cancers14143488 |
2022 |
Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review. |
CXCR4 |
| 28 |
35954476 |
10.3390/cancers14153814 |
2022 |
The Role of [<sup>68</sup>Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review. |
CXCR4 |
| 29 |
36030395 |
10.1111/ejh.13856 |
2022 |
A comparison of four leukapheresis methods to harvest an optimal dose of CD34+ cells: A single center experience. |
CXCR4 |
| 30 |
36048893 |
10.1093/ajcp/aqac104 |
2022 |
Systemic Presentation of Somatic TET2 Mutated B-Cell Lymphoma in a Child With Kabuki Syndrome and a Germline KMT2D Variant. |
CXCR4 |
| 31 |
32795528 |
10.1016/j.jid.2020.06.034 |
2021 |
Cancer-Associated Fibroblasts in Mycosis Fungoides Promote Tumor Cell Migration and Drug Resistance through CXCL12/CXCR4. |
CXCR4 |
| 32 |
32810857 |
10.1159/000509286 |
2021 |
Current and Emerging Treatments for Waldenström Macroglobulinemia. |
CXCR4 |
| 33 |
33131073 |
10.1111/exd.14228 |
2021 |
The role of Dipeptidyl Peptidase-4 in cutaneous disease. |
CXCR4 |
| 34 |
33206936 |
10.1182/blood.2020005650 |
2021 |
Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia. |
CXCR4 |
| 35 |
33208624 |
10.1097/RLU.0000000000003404 |
2021 |
Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI. |
CXCR4 |
| 36 |
33253591 |
10.1021/acs.molpharmaceut.0c00785 |
2021 |
High-Contrast CXCR4-Targeted <sup>18</sup>F-PET Imaging Using a Potent and Selective Antagonist. |
CXCR4 |
| 37 |
33391493 |
10.7150/thno.48620 |
2021 |
CXCR4 PET imaging of mantle cell lymphoma using [<sup>68</sup>Ga]Pentixafor: comparison with [<sup>18</sup>F]FDG-PET. |
CXCR4 |
| 38 |
33579803 |
10.2967/jnumed.120.257279 |
2021 |
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT. |
CXCR4 |
| 39 |
33604348 |
10.3389/fmed.2021.609116 |
2021 |
YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical Trial. |
CXCR4 |
| 40 |
33612450 |
10.1016/j.transci.2021.103070 |
2021 |
First experience of the use of a generic of plerixafor in peripheral blood stem cell mobilization in multiple myeloma and lymphoma patients. |
CXCR4 |
| 41 |
33660512 |
10.1021/acs.jmedchem.1c00066 |
2021 |
Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors. |
CXCR4 |
| 42 |
33716502 |
10.2147/IJN.S289733 |
2021 |
Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4<sup>+</sup> Diffuse Large B-Cell Lymphoma Cells. |
CXCR4 |
| 43 |
33735664 |
10.1016/j.neo.2021.02.002 |
2021 |
Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. |
CXCR4 |
| 44 |
33856274 |
10.1080/10428194.2021.1913150 |
2021 |
Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma. |
CXCR4 |
| 45 |
33934404 |
10.1002/jcla.23784 |
2021 |
PCR array analysis identified hyperproliferation but not autophagy or apoptosis in fibrous epulis. |
CXCR4 |
| 46 |
34083646 |
10.1038/s41598-021-91112-7 |
2021 |
DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity. |
CXCR4 |
| 47 |
34093792 |
10.7150/jca.54952 |
2021 |
Aggregative Perivascular Tumor Cell Growth Pattern of Primary Central Nervous System Lymphomas Is Associated with Hypoxia-Related Endoplasmic Reticulum Stress. |
CXCR4 |
| 48 |
34106998 |
10.1371/journal.ppat.1009618 |
2021 |
Epigenetic Plasticity Enables CNS-Trafficking of EBV-infected B Lymphocytes. |
CXCR4 |
| 49 |
34172595 |
10.1097/RLU.0000000000003760 |
2021 |
Chemokine Receptor 4-Targeted 68Ga-Pentixafor PET/CT in Response Assessment of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT. |
CXCR4 |
| 50 |
34187383 |
10.1186/s12876-021-01844-z |
2021 |
Tumor-to-tumor metastasis of diffuse large B cell lymphoma to gastric adenocarcinoma via CXCL12 (SDF-1)/CXCR4 axis: a case report. |
CXCR4 |
| 51 |
34255748 |
10.1172/JCI143119 |
2021 |
Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia. |
CXCR4 |
| 52 |
34269725 |
10.1097/RLU.0000000000003817 |
2021 |
CXCR4 Expression Demonstrated by 68Ga-Pentixafor PET/CT Imaging in a Case of Systemic Mastocytosis Mimicking Lymphoma. |
CXCR4 |
| 53 |
34307181 |
10.3389/fonc.2021.710900 |
2021 |
Somatostatin Receptors and Chemokine Receptor CXCR4 in Lymphomas: A Histopathological Review of Six Lymphoma Subtypes. |
CXCR4 |
| 54 |
34363012 |
10.1038/s41375-021-01376-1 |
2021 |
CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness. |
CXCR4 |
| 55 |
34404617 |
10.1016/j.transci.2021.103240 |
2021 |
An innovation in stem cell harvesting: Heparin use. |
CXCR4 |
| 56 |
34490994 |
10.1002/pbc.29319 |
2021 |
Single-center results reporting improved hematopoietic stem cell mobilization success in pediatric and young adult patients with solid tumors and lymphoma. |
CXCR4 |
| 57 |
34570179 |
10.1182/bloodadvances.2021004668 |
2021 |
Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. |
CXCR4 |
| 58 |
34583709 |
10.1186/s12943-021-01419-2 |
2021 |
Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma. |
CXCR4 |
| 59 |
34714390 |
10.1186/s13550-021-00852-0 |
2021 |
Semi-quantitative measurements of chemokine receptor 4-targeted <sup>68</sup>Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. |
CXCR4 |
| 60 |
34793563 |
10.1371/journal.pone.0260186 |
2021 |
Investigating CXCR4 expression of tumor cells and the vascular compartment: A multimodal approach. |
CXCR4 |
| 61 |
34990523 |
10.4143/crt.2021.944 |
2021 |
Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia During R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma. |
CXCR4 |
| 62 |
35087759 |
10.3389/fonc.2021.801124 |
2021 |
Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia. |
CXCR4 |
| 63 |
31248974 |
10.3324/haematol.2018.211490 |
2020 |
A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models. |
CXCR4 |
| 64 |
31260155 |
10.1002/jmri.26848 |
2020 |
MRI and PET/MRI in hematologic malignancies. |
CXCR4 |
| 65 |
31471373 |
10.3324/haematol.2019.216218 |
2020 |
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. |
CXCR4 |
| 66 |
31476465 |
10.1016/j.wneu.2019.08.140 |
2020 |
T140 Inhibits Apoptosis and Promotes Proliferation and Matrix Formation Through the SDF-1/CXC Receptor-4 Signaling Pathway in Endplate Chondrocytes of the Rat Intervertebral Discs. |
CXCR4 |
| 67 |
31605845 |
10.1016/j.wneu.2019.09.158 |
2020 |
Primary Intra-Axial Diffuse Large B-Cell Lymphoma in Immunocompetent Patients: Clinical Impact of Molecular Analysis and Histogenetic Evaluation. |
CXCR4 |
| 68 |
31719683 |
10.1038/s41375-019-0628-0 |
2020 |
Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma. |
CXCR4 |
| 69 |
31768009 |
10.1038/s41409-019-0756-1 |
2020 |
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma. |
CXCR4 |
| 70 |
31902622 |
10.1016/j.pathol.2019.11.002 |
2020 |
A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. |
CXCR4 |
| 71 |
31960730 |
10.1080/10428194.2020.1711901 |
2020 |
Waldenstrom's macroglobulinemia in the era of immunotherapy. |
CXCR4 |
| 72 |
31980558 |
10.1136/jclinpath-2019-206282 |
2020 |
Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS. |
CXCR4 |
| 73 |
32083995 |
10.1200/JCO.19.02314 |
2020 |
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. |
CXCR4 |
| 74 |
32296856 |
10.1007/s00117-020-00676-4 |
2020 |
[Hybrid imaging in lymphoma]. |
CXCR4 |
| 75 |
32332145 |
10.2967/jnumed.120.241703 |
2020 |
CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma. |
CXCR4 |
| 76 |
32370190 |
10.3390/cancers12051143 |
2020 |
Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells. |
CXCR4 |
| 77 |
32373205 |
10.7150/thno.43231 |
2020 |
Selective delivery of T22-PE24-H6 to CXCR4<sup>+</sup> diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model. |
CXCR4 |
| 78 |
32544428 |
10.1016/j.phrs.2020.105010 |
2020 |
CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent. |
CXCR4 |
| 79 |
32694049 |
10.1016/j.clml.2020.05.003 |
2020 |
De Novo CD5<sup>+</sup> Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances. |
CXCR4 |
| 80 |
32724470 |
10.7150/thno.45537 |
2020 |
A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency. |
CXCR4 |
| 81 |
32757068 |
10.1186/s13550-020-00681-7 |
2020 |
Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [<sup>68</sup>Ga]pentixafor in non-Hodgkin lymphoma: comparison to [<sup>18</sup>F]FDG. |
CXCR4 |
| 82 |
32766282 |
10.3389/fmolb.2020.00164 |
2020 |
High-Throughput Screening of a Functional Human CXCL12-CXCR4 Signaling Axis in a Genetically Modified <i>S. cerevisiae</i>: Discovery of a Novel Up-Regulator of CXCR4 Activity. |
CXCR4 |
| 83 |
32913458 |
10.7150/jca.48748 |
2020 |
Safety, Efficacy, Pharmacokinetic and Pharmacodynamic evaluation of YF-H-2015005 for mobilizing Hematopoietic stem cells in Non-Hodgkin's Lymphoma Patients. |
CXCR4 |
| 84 |
32955949 |
10.1080/14728214.2020.1822816 |
2020 |
Emerging drugs for the treatment of Waldenström macroglobulinemia. |
CXCR4 |
| 85 |
33154951 |
10.3389/fonc.2020.591577 |
2020 |
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies. |
CXCR4 |
| 86 |
33252851 |
10.1002/ctm2.221 |
2020 |
Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma. |
CXCR4 |
| 87 |
33275726 |
10.1182/hematology.2020000121 |
2020 |
Management of Waldenström macroglobulinemia in 2020. |
CXCR4 |
| 88 |
29777009 |
10.2967/jnumed.118.210997 |
2019 |
Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma. |
CXCR4 |
| 89 |
29954928 |
10.3324/haematol.2017.180505 |
2019 |
Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. |
CXCR4 |
| 90 |
30290030 |
10.1002/stem.2912 |
2019 |
Microvesicles Secreted by Nitric Oxide-Primed Mesenchymal Stromal Cells Boost the Engraftment Potential of Hematopoietic Stem Cells. |
CXCR4 |
| 91 |
30333224 |
10.1158/1078-0432.CCR-18-1047 |
2019 |
Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies. |
CXCR4 |
| 92 |
30623224 |
10.1007/s00347-018-0840-8 |
2019 |
[New molecular pathological strategies for malignant iris tumors]. |
CXCR4 |
| 93 |
30774774 |
10.18632/oncotarget.26588 |
2019 |
High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients. |
CXCR4 |
| 94 |
30776910 |
10.1177/2040206619829382 |
2019 |
Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration. |
CXCR4 |
| 95 |
30836379 |
10.1038/s41586-019-1027-4 |
2019 |
HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. |
CXCR4 |
| 96 |
30883140 |
10.1021/acs.molpharmaceut.9b00069 |
2019 |
Development and Evaluation of an <sup>18</sup>F-Radiolabeled Monocyclam Derivative for Imaging CXCR4 Expression. |
CXCR4 |
| 97 |
30904045 |
10.1016/j.amjms.2019.01.008 |
2019 |
CXCR4 and CCR7 Expression in Primary Nodal Diffuse Large B-Cell Lymphoma-A Clinical and Immunohistochemical Study. |
CXCR4 |
| 98 |
30966844 |
10.1080/21505594.2019.1605803 |
2019 |
The roles of apoptosis, autophagy and unfolded protein response in arbovirus, influenza virus, and HIV infections. |
CXCR4 |
| 99 |
30985424 |
10.1097/RLU.0000000000002574 |
2019 |
68Ga CXCR-4 PET/CT Imaging in an Atypical Case of Extramedullary Plasmacytoma Mimicking as Renal Cell Carcinoma. |
CXCR4 |
| 100 |
31004184 |
10.1007/s00259-019-04322-7 |
2019 |
[<sup>68</sup>Ga]Pentixafor PET/MR imaging of chemokine receptor 4 expression in the human carotid artery. |
CXCR4 |
Datasets
Models
